MarketCap
Facebook
X
Telegram
USANA Health Sciences Income Statement 2026-2009 | USNA
Brief overview of income trends at USANA Health Sciences
The conclusions below are based on five years of reported results. The revenue attributed to USANA Health Sciences moved from $1.1 billion to $925 million between the two endpoints. The cumulative result was −18.5%, corresponding to roughly −4% per year. The negative rate indicates weakening core operations.
The gross result shifted from 926 million dollars to 724 million dollars, or −21.7%. Cost of revenue developed less favorably than sales and pressured gross profitability. Comparing the endpoints gives gross margins of 81.6% and 78.3%. The contraction points to pressure from direct costs or weaker pricing power.
EBITDA changed from $190 million to $70 million (−63.2%). EBITDA underperformed the top-line trend. EBITDA margin was 16.8% at the start and 7.6% at the end. The margin contraction indicates weaker operating efficiency.
The five-year change in net income was −91.4%: from 125 million dollars to 10.8 million dollars. The final result developed less favorably than the core business.
The market value of the business moved from $2.1 billion to $325 million, or −84.8%. The negative valuation trend points to increased investor caution.
Financial takeaway
Signs of deterioration dominate the five-year picture. Caution is warranted because of pressure from direct costs, lower investor confidence and weaker operating efficiency. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement USANA Health Sciences
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
325 M | 335 M | 931 M | 1.18 B | 2.14 B | - | 1.52 B | 2.82 B | 1.87 B | 1.73 B | 1.38 B | - | 841 M | 551 M | 605 M | 273 M | - |
Shares |
18.5 M | 19.1 M | 19.2 M | 19.3 M | 21.2 M | - | 22.8 M | 24.6 M | 24.7 M | 26.4 M | 27.4 M | - | 28.4 M | 29.8 M | 31.9 M | 15.3 M | - |
Historical Prices |
17.5 | 17.5 | 48.3 | 61.1 | 101 | 77.1 | 78.5 | 118 | 74 | 61.2 | 63.9 | 51.3 | 37.8 | 16.5 | 15.2 | 17.8 | 13.5 |
Net Income |
10.8 M | 42 M | 63.8 M | 69.4 M | 125 M | - | 101 M | 126 M | 62.5 M | 94.7 M | 76.6 M | - | 79 M | 66.4 M | 45.7 M | 33.6 M | - |
Revenue |
925 M | 855 M | 921 M | 999 M | 1.13 B | - | 1.06 B | 1.19 B | 1.05 B | 918 M | 790 M | - | 718 M | 649 M | 518 M | - | - |
Cost of Revenue |
201 M | 161 M | 177 M | 194 M | 209 M | - | 188 M | 201 M | 179 M | 180 M | - | - | - | - | - | - | - |
Gross Profit |
724 M | 693 M | 744 M | 805 M | 926 M | - | 873 M | 989 M | 868 M | 759 M | 650 M | - | 591 M | 533 M | 422 M | 347 M | - |
Operating Income |
37.4 M | 66.3 M | 93.1 M | 108 M | 176 M | - | 146 M | 188 M | 133 M | 139 M | 116 M | - | 117 M | 98.2 M | 77.3 M | 50.8 M | - |
Interest Expense |
2.52 M | -1.01 M | 262 K | 192 K | 507 K | - | 66 K | 36 K | 46 K | 444 K | 129 K | - | 1 K | 20 K | 9 K | 609 K | - |
EBITDA |
70 M | 80.9 M | 106 M | 121 M | 190 M | - | 161 M | 205 M | 149 M | 152 M | 125 M | - | 126 M | 107 M | 76.1 M | 57.9 M | - |
Operating Expenses |
687 M | 627 M | 651 M | 697 M | 749 M | - | 727 M | 800 M | 735 M | 617 M | 534 M | - | 474 M | 435 M | 354 M | 296 M | - |
General and Administrative Expenses |
337 M | 263 M | 257 M | 262 M | 261 M | - | 717 M | 791 M | 726 M | 611 M | 528 M | - | 469 M | 430 M | 354 M | 100 M | - |
All numbers in USD currency
Quarterly Income Statement USANA Health Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18.4 M | 18.3 M | 18.5 M | 19 M | 19.1 M | 19.1 M | 19.1 M | 19.2 M | 19.1 M | 19.2 M | 19.3 M | 19.3 M | 19.2 M | 19.2 M | 19.2 M | 19.4 M | 21 M | 20 M | 20.2 M | 20.9 M | - | 21 M | 21 M | 21.5 M | 21.7 M | 22.2 M | 23.2 M | 23.5 M | 23.6 M | 24.3 M | 24.2 M | 24.1 M | 24 M | 24.3 M | 24.6 M | 24.5 M | 24.5 M | 24.2 M | 24 M | 24.2 M | 12.6 M | 12.9 M | 12.7 M | 12.6 M | - | 12.9 M | 13.8 M | 13.9 M | 13.9 M | 13.8 M | 13.5 M | 13.6 M | 13.8 M | 14.4 M | 14.7 M | 15 M | 14.9 M | 15 M | 15.5 M | 15.9 M |
Net Income |
7.52 M | -6.52 M | 9.66 M | 9.4 M | - | 10.6 M | 10.4 M | 16.5 M | - | 11.3 M | 17.3 M | 18.4 M | - | 14.9 M | 19.2 M | 22.5 M | - | 27.3 M | 38.2 M | 30.6 M | - | 30.5 M | 28 M | 26.6 M | 30.8 M | 24.2 M | 21.4 M | 24.2 M | 32.3 M | 31 M | 33.9 M | 28.9 M | -5.85 M | 23.8 M | 23.3 M | 21.4 M | 21.9 M | 30.1 M | 25.8 M | 22.3 M | 21.3 M | 25.6 M | 25.4 M | 19.7 M | - | 19.5 M | 19.3 M | 16.5 M | 20.3 M | 16.8 M | 24.2 M | 17.8 M | 18.4 M | 17.5 M | 16.7 M | 13.8 M | 13.2 M | 12.4 M | 13.9 M | 11.4 M |
Revenue |
250 M | 214 M | 236 M | 250 M | - | 200 M | 213 M | 228 M | - | 213 M | 238 M | 248 M | - | 233 M | 264 M | 273 M | - | 274 M | 337 M | 308 M | - | 299 M | 259 M | 267 M | 271 M | 261 M | 256 M | 273 M | 299 M | 297 M | 301 M | 292 M | 273 M | 262 M | 257 M | 255 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
59.4 M | 48.8 M | 50.2 M | 52.4 M | - | 39.3 M | 40.3 M | 43.1 M | - | 42.5 M | 43.3 M | 48.5 M | - | 46.6 M | 49.5 M | 51.4 M | - | 50.7 M | 57 M | 57.7 M | - | 56.4 M | 47.7 M | 46.1 M | - | 47.8 M | 46.5 M | 45.9 M | - | 51.9 M | 50 M | 49.4 M | - | 47.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
191 M | 165 M | 186 M | 197 M | - | 161 M | 173 M | 185 M | - | 171 M | 195 M | 200 M | - | 187 M | 215 M | 221 M | - | 224 M | 280 M | 250 M | - | 242 M | 211 M | 221 M | 224 M | 213 M | 210 M | 227 M | 250 M | 245 M | 251 M | 243 M | 227 M | 215 M | 213 M | 213 M | 207 M | 209 M | 213 M | 198 M | 190 M | 192 M | 193 M | 181 M | - | 157 M | 153 M | 149 M | 152 M | 142 M | 157 M | 139 M | 138 M | 135 M | 133 M | 127 M | 121 M | 118 M | 123 M | 118 M |
Operating Income |
13.9 M | 1.22 M | 16.7 M | 15.7 M | - | 15.6 M | 17.8 M | 24.7 M | - | 17.6 M | 24.4 M | 26.8 M | - | 22.6 M | 29.4 M | 33.1 M | - | 40.8 M | 53.7 M | 44.2 M | - | 45.4 M | 39.6 M | 39 M | - | 35.5 M | 31.2 M | 35 M | - | 45.5 M | 51.1 M | 43.1 M | - | 31.4 M | 32.4 M | 32.9 M | - | 35.8 M | 37.4 M | 33.5 M | - | 38 M | 38.8 M | 29.8 M | - | 29.3 M | 29.1 M | 25.1 M | - | 24.7 M | 36.5 M | 26.6 M | - | 24.1 M | 25.2 M | 20.9 M | - | 18.8 M | 21.2 M | 17.2 M |
Interest Expense |
1.39 M | 41 K | 1.74 M | 756 K | - | -86 K | -349 K | -186 K | - | 234 K | 229 K | 31 K | - | 32 K | 96 K | 32 K | - | 18 K | 16 K | 5 K | - | 1.38 M | 217 K | 21 K | - | 22 K | 10 K | 12 K | - | 8 K | 9 K | 10 K | - | 10 K | 11 K | 10 K | - | 46 K | 176 K | 202 K | - | 4 K | 7 K | 14 K | - | 5 K | 6 K | 6 K | - | -43 K | -164 K | -104 K | - | 11 K | -293 K | 94 K | - | 1 K | 2 K | 6 K |
EBITDA |
22.2 M | 9.14 M | 24.5 M | 24 M | - | 19.2 M | 21.7 M | 27.8 M | - | - | - | 30.1 M | - | 32.7 M | 36 M | 36.3 M | - | 50.5 M | 60.2 M | 47.4 M | - | 45.4 M | 39.6 M | 42.5 M | - | 46.6 M | 38.8 M | 38.9 M | - | 58.2 M | 59.8 M | 47.7 M | - | 43.2 M | 40 M | 36.4 M | - | 45.8 M | 44.2 M | 37 M | - | 45.2 M | 43.4 M | 32.1 M | - | 35.9 M | 33.5 M | 27.3 M | - | 31.6 M | 41.1 M | 28.9 M | - | 30.7 M | 29.6 M | 23.1 M | - | 25.1 M | 25.4 M | 19.4 M |
Operating Expenses |
177 M | 164 M | 169 M | 181 M | - | 145 M | 155 M | 160 M | - | 153 M | 170 M | 173 M | - | 164 M | 186 M | 188 M | - | 183 M | 226 M | 206 M | - | 197 M | 172 M | 182 M | - | 177 M | 178 M | 192 M | - | 199 M | 200 M | 199 M | - | 183 M | 181 M | 180 M | - | 173 M | 175 M | 164 M | - | 154 M | 154 M | 151 M | - | 128 M | 124 M | 123 M | - | 118 M | 121 M | 112 M | - | 111 M | 108 M | 106 M | - | 99.5 M | 102 M | 101 M |
General and Administrative Expenses |
88.3 M | 85.9 M | 81.9 M | 91.4 M | - | 61.3 M | 64.3 M | 64.3 M | - | 63.3 M | 68.1 M | 66.9 M | - | 66 M | 66.4 M | 68.8 M | - | 66.6 M | 72.2 M | 71.6 M | - | 65.7 M | 60.9 M | 65.5 M | - | 66.3 M | 66.9 M | 69.6 M | - | 69.1 M | 67.5 M | 70.1 M | - | 67.3 M | 62.4 M | 64 M | - | 60.6 M | 59.8 M | 56.6 M | - | 52.8 M | 52.5 M | 49.9 M | - | 45.5 M | 43.2 M | 44.6 M | - | 41.1 M | 43 M | 42.4 M | - | 40.3 M | 36.8 M | 38 M | - | 33.4 M | 33.8 M | 35.9 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company USANA Health Sciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Household products industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Natura &Co Holding S.A.
NTCO
|
- | - | $ 9.02 B | - |
 |
United-Guardian
UG
|
$ 7.05 | -2.35 % | $ 32.4 M |  USA |
 |
Unilever PLC
UL
|
$ 63.41 | -2.85 % | $ 138 B |  Britain |
 |
Dogness (International) Corporation
DOGZ
|
$ 0.88 | 0.34 % | $ 11.8 M |  China |
 |
Revlon
REV
|
- | -4.41 % | $ 212 M | USA |
 |
e.l.f. Beauty
ELF
|
$ 82.89 | 0.77 % | $ 4.54 B | USA |
 |
Coty
COTY
|
$ 2.75 | 2.04 % | $ 2.39 B | USA |
 |
Hims & Hers Health
HIMS
|
$ 27.77 | 2.7 % | $ 6.25 B | USA |
 |
Helen of Troy Limited
HELE
|
$ 27.63 | -0.9 % | $ 636 M |  Bermuda |
 |
Acme United Corporation
ACU
|
$ 56.86 | 1.12 % | $ 215 M | USA |
 |
Edgewell Personal Care Company
EPC
|
$ 27.19 | -0.22 % | $ 1.29 B | USA |
 |
The Clorox Company
CLX
|
$ 95.53 | -1.24 % | $ 11.8 B | USA |
 |
Church & Dwight Co.
CHD
|
$ 98.81 | 1.16 % | $ 24 B | USA |
 |
Newell Brands
NWL
|
$ 5.6 | 8.95 % | $ 2.34 B | USA |
 |
Kimberly-Clark Corporation
KMB
|
$ 109.31 | -0.8 % | $ 36.3 B | USA |
 |
Nature's Sunshine Products
NATR
|
$ 20.15 | -0.69 % | $ 363 M | USA |
 |
Nu Skin Enterprises
NUS
|
$ 5.19 | -0.76 % | $ 256 M | USA |
 |
Spectrum Brands Holdings
SPB
|
$ 88.77 | - | $ 2.28 B | USA |
 |
LifeVantage Corporation
LFVN
|
$ 6.43 | 2.23 % | $ 78.8 M | USA |
 |
The Estée Lauder Companies
EL
|
$ 83.9 | -1.15 % | $ 30.2 B | USA |
 |
The Procter & Gamble Company
PG
|
$ 144.49 | 0.37 % | $ 340 B | USA |
 |
Mannatech, Incorporated
MTEX
|
$ 4.79 | -1.84 % | $ 9.11 M | USA |
 |
Colgate-Palmolive Company
CL
|
$ 91.3 | -0.37 % | $ 73.8 B | USA |
 |
Inter Parfums
IPAR
|
$ 124.55 | -0.81 % | $ 4 B | USA |